Impact of High-Risk Cytogenetics and Achievement of Molecular Remission on Long-Term Freedom from Disease after Autologous–Allogeneic Tandem Transplantation in Patients with Multiple Myeloma-Reference-Cited by-同舟云学术

Impact of High-Risk Cytogenetics and Achievement of Molecular Remission on Long-Term Freedom from Disease after Autologous–Allogeneic Tandem Transplantation in Patients with Multiple Myeloma

Published:2013-03 Issue:3 Volume:19 Page:398-404
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Kröger Nicolaus,Badbaran Anita,Zabelina Tatjana,Ayuk Francis,Wolschke Christine,Alchalby Haefaa,Klyuchnikov Evgeny,Atanackovic Djordje,Schilling Georgia,Hansen Timon,Schwarz Sabine,Heinzelmann Marion,Zeschke Silke,Bacher Ulrike,Stübig Thomas,Fehse Boris,Zander Axel R.

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference39 articles.

1. Remission status defined by immunofixation vs. electrophoresis after autologous transplantation has a major impact on the outcome of multiple myeloma patients;Lahuerta;Br J Haematol,2000

2. Prognostic impact of posttransplantation complete remission in multiple myeloma: final results of a prospective study in a series of homogenously treated patients;Martinez-Lopez;Haematologica,2007

3. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells;Corradini;J Clin Oncol,1999

4. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma;Martinelli;J Clin Oncol,2000

5. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma;Corradini;Blood,2003

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years;Frontiers in Oncology;2024-07-31

2. Allogeneic stem cell transplantation in multiple myeloma: is there still a place?;Frontiers in Oncology;2024-06-04

3. Bortezomib Maintenance After Allogeneic Transplantation in Newly Diagnosed Myeloma Patients Results in Decreased Incidence and Severity of Chronic GVHD;Transplantation and Cellular Therapy;2023-01

4. Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study;Bone Marrow Transplantation;2021-11-29

5. Allogeneic Stem Cell Transplantation in Patients with High-Risk Multiple Myeloma: Utopia or Continuous Challenge in Aiming for Cure?;Current Treatment Options in Oncology;2021-06-10